| Patient | Rachel Carson |
|---|---|
| Date of birth | 1973-05-27 |
| Identifiers | MRN HR-ML041-SYN; SSN (made up) 000-41-5068 |
| Document date | 2026-04-20 |
| Author | Margaret Vance-Okonkwo, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Review two weeks after left lumpectomy, with the pathology. [S]
Ms. Carson returns two weeks after a left lumpectomy with sentinel lymph node biopsy. The germline panel before surgery showed no pathogenic variant. She asked to hear the pathology in full and had it from Dr. Solís-Abernathy last week, and again today: the cancer was 2.3 cm, grade 2, with clear margins, and two of the three sentinel lymph nodes contained cancer, without spread beyond the node capsules (pT2 pN1a, anatomic stage IIB). She was told plainly that the cancer had reached lymph nodes under the arm, that this raises the chance of it returning, and that treatment is still given with the aim of cure. The recurrence score is 17. Last week the multidisciplinary breast team (surgery, medical oncology, and radiation oncology) reviewed the results and gave her their recommendations with the expected benefits and side effects in numbers; she took a week to read about them and has decided. The urea breath test three days ago, two weeks after she stopped omeprazole, was negative. The wound has healed and she has little pain on acetaminophen. She is writing again in the mornings. [S]
| Element | Detail |
|---|---|
| Interval change | Left lumpectomy and sentinel node biopsy two weeks ago |
| Pathology | pT2 pN1a(sn), 2 of 3 sentinel nodes, grade 2, margins clear; recurrence score 17 |
| Genetics | No pathogenic germline variant |
| Her decisions | Radiation; letrozole with ribociclib; zoledronic acid; no chemotherapy |
| Ulcer | Urea breath test negative; Helicobacter pylori eradicated |
| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | No fever; energy returning |
| Integumentary | Negative | Wounds healed; no redness or fluid |
| Musculoskeletal | Positive | Mild tightness raising the left arm; knee stiffness unchanged; no bone pain |
| Neurological | Positive | Small patch of numbness on the inner left upper arm |
| Gastrointestinal | Negative | No indigestion or black stools off omeprazole |
| Psychiatric | Positive | Some worry about the lymph nodes, sleeping better; PHQ-9 4, GAD-7 5 |
6 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Omeprazole 20 mg delayed-release oral capsule, one capsule by mouth once daily before breakfast, to complete eight weeks of ulcer healing | One capsule once daily before breakfast | Oral route | 2026-01-19 to 2026-04-03 | completed | S |
| Acetaminophen 500 mg oral tablet, two tablets (1000 mg) by mouth up to three times a day as needed for knee pain, no more than 3000 mg a day | Two tablets up to every 8 hours as needed | Oral route | 2025-06-02 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-04-20 | Body height | 163 | cm | S |
| 2026-04-20 | Body weight | 58.6 | kg | S |
| 2026-04-20 | Body mass index (BMI) [Ratio] | 22.1 | kg/m2 | S |
| 2026-04-20 | Systolic blood pressure | 122 | mm[Hg] | S |
| 2026-04-20 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 2026-04-20 | Heart rate | 74 | /min | S |
| 2026-04-20 | Respiratory rate | 14 | /min | S |
| 2026-04-20 | Body temperature | 36.7 | Cel | S |
| 2026-04-20 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-04-20 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 4 | {score} | S | ||
| 2026-04-20 | Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] | 5 | {score} | S |
Vital signs recorded on 2026-04-20; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well and composed |
| Breasts | Left lumpectomy scar at 2 o'clock and axillary incision healed; mild firmness under the scar; no fluid or erythema. Right breast normal |
| Lymph nodes | No palpable axillary or supraclavicular nodes |
| Extremities | Arm circumference 25.5 cm on each side 10 cm above the elbow, the same as before surgery; left shoulder flexion 160 degrees |
| Abdomen | Soft; no epigastric tenderness |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Invasive ductal carcinoma of the left breast, upper outer quadrant at 2 o'clock, 2.4 cm on imaging; core biopsy grade 2, estrogen and progesterone receptor positive, HER2 negative, Ki-67 22 percent; clinical stage T2 N0 (cT2 cN0 M0); synthetic modern counterpart of the documented 1960 breast cancer, which was not disclosed to her | active | confirmed | C50.412 | S — Synthetic tumor details, stage, and treatment; the breast lumps, the 1960 operation, and the nondisclosure are documented (D), but no tumor details from her lifetime are used. |
| Estrogen receptor positive status of the breast cancer (ER 95 percent, PR 80 percent) | active | confirmed | Z17.0 | S — Synthetic receptor result; no receptor status from her lifetime is known. |
| New firm lump in the upper outer quadrant of the left breast, found two weeks ago; clinically suspicious; diagnostic imaging and biopsy booked | resolved | confirmed | N63.21 | S — Synthetic presenting concern at the index visit, superseded by the biopsy diagnosis; the lumps in the left breast in early 1960 are documented (D). |
| Duodenal ulcer found at endoscopy seven weeks ago, with Helicobacter pylori on biopsy; treated with 14 days of bismuth quadruple therapy and completing eight weeks of omeprazole; test of cure planned | resolved | confirmed | K26.9 | S — Synthetic modern ulcer; it echoes the ulcer among her documented illnesses, which the sources do not date. |
| Primary osteoarthritis of both knees, mild, with stiffness after long walks on the shore | active | confirmed | M17.0 | S — Synthetic condition; it is not linked to the documented word arthritis, which she may have used to keep her cancer private. |
| Metastatic carcinoma in two of three left axillary sentinel lymph nodes (macrometastases, no extranodal extension); pathologic stage pT2 pN1a(sn) M0, anatomic stage IIB; recurrence score 17 | active | confirmed | C77.3 | S — Synthetic surgical pathology; spread to lymph nodes is documented later in her life, but no pathology from her lifetime is used. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Post-operative wound, shoulder, and arm check | After surgery | Completed today | Wounds healed; shoulder flexion 160 degrees; no seroma |
| Laboratory | Surgical pathology and recurrence score | After surgery | Up to date | pT2 pN1a(sn), margins clear; recurrence score 17 |
| Laboratory | Germline genetic testing | At diagnosis | Up to date | No pathogenic variant; result given before surgery |
| Self-management | Disclosure of the pathology and shared decision-making | At every result | Completed today | Pathology given in full in plain words with a copy; benefits and harms of each treatment given in numbers; decisions made by her after a week to consider them |
| Examination | Lymphedema assessment and risk-reduction counseling | Every visit | Completed today | 25.5 cm on each side, unchanged from the pre-operative baseline; counseled on early signs |
| Referral | Medical and radiation oncology | After surgery | Up to date | Seen last week at the multidisciplinary breast clinic |
| Imaging | CT, bone scan, or PET for distant spread | Only with symptoms or clinical stage III | Not indicated | Pathologic stage IIB without symptoms of spread |
| Laboratory | Tumor markers | Not recommended for early breast cancer | Not indicated | Not ordered |
| Medication safety | Ribociclib baseline ECG, blood count, liver tests, and electrolytes | Before the first dose | Due | At the visit when letrozole and ribociclib start, after radiation |
| Imaging | Bone density (DXA) | Baseline at aromatase inhibitor start | Ordered | Booked for the day letrozole starts |
| Medication safety | Dental assessment before zoledronic acid | Before the first infusion | Ordered | Dental check booked before the first infusion |
| Survey | Distress, depression, and anxiety screen (PHQ-9 and GAD-7) | At periodic intervals | Completed today | PHQ-9 4 and GAD-7 5 |
| Laboratory | Helicobacter pylori test of cure | At least four weeks after antibiotics and two weeks off a proton pump inhibitor | Up to date | Urea breath test three days ago: negative |
Goal progress:
Guideline basis: NCCN Clinical Practice Guidelines in Oncology: Breast Cancer, Version 5.2025 (2025); Code of Medical Ethics Opinion 2.1.3: Withholding Information from Patients (2016); Management of the Axilla in Early-Stage Breast Cancer: Ontario Health (Cancer Care Ontario) and ASCO Guideline. J Clin Oncol 2021;39(27):3056-3082 (2021); Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer-Cyclin-Dependent Kinase 4 and 6 Inhibitors: ASCO Guideline Rapid Recommendation Update. J Clin Oncol 2024;42(18):2233-2235 (2024); Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: ASCO-OH (CCO) Guideline Update. J Clin Oncol 2022;40(7):787-800 (2022); ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. Am J Gastroenterol 2024;119(9):1730-1753 (2024)
Follow-up: Radiation starting in two weeks. Primary care visit after radiation, on the day letrozole and ribociclib start. Next scheduled visit 2026-06-15: start of letrozole, ribociclib, and zoledronic acid after radiation. [S]